Minireviews
Copyright ©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 7, 2013; 19(41): 7055-7061
Published online Nov 7, 2013. doi: 10.3748/wjg.v19.i41.7055
Table 2 IFNL3 polymorphisms and steatosis in chronic hepatitis C
No. of patientsStudy designHCV genotypeIFNL3 SNPResultsEthnicityRef.
1604RetrospectiveHCV-1rs12979860CC genotype associated with higher pretreatment LDL-C levels and less frequent hepatic steatosisCaucasians46
145180Retrospective analysis of two Independent cohorts: (1) (antifibrotic) Study cohort; (2) Duke cohortHCV-1rs12979860CC genotype associated with less hepatic steatosis122 (84.1%) Caucasians130 (72.2%) Caucasians47
434multi-center, RetrospectiveHCV-1rs12979860CC genotype associated with less frequent hepatic steatosisCaucasians48
202ProspectiveHCV-1: 181 (89.6%)rs12979860CC genotype associated with less frequent hepatic steatosisCaucasians49
HCV-4: 21 (10.4%)
153RetrospectiveHCV-1brs8099917TT genotype associated with less hepatic steatosis (vesicular and clear cell changes)Japanese50
626Retrospective analysis of the Swiss Hepatitis C Cohort StudyNon-HCV-3rs12980275G associated with less hepatic steatosis only in non-HCV-3Caucasians51
122RetrospectiveHCV-1brs8099917No association with hepatic steatosisJapanese Mongolian52
445RetrospectiveHCV-1: 303 (68.1%)rs12979860No association with hepatic steatosisCaucasian53
HCV-2: 13 (2.9%)
HCV-3: 82 (18.4%)
HCV-4: 47 (10.6%)